This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Ventyx Biosciences Stock (NASDAQ:VTYX) Get Ventyx Biosciences alerts:Sign Up Key Stats Today's Range$13.99▼$14.0050-Day Range$13.91▼$14.0052-Week Range$0.78▼$25.00Volume5.45 million shsAverage Volume3.32 million shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingHold Company Overview Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California. Read More Ventyx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreVTYX MarketRank™: 0.111925383075 of 5 starsVentyx Biosciences scored higher than 2% of companies evaluated by MarketBeat, and ranked 895th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingVentyx Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 8 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Ventyx Biosciences is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageVentyx Biosciences has received no research coverage in the past 90 days.Read more about Ventyx Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.09) to ($2.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VTYX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for VTYX on MarketBeat in the last 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders14.49% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.88% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ventyx Biosciences' insider trading history. Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VTYX Stock News HeadlinesVentyx Biosciences Shareholders Approve Merger With Eli LillyJune 12, 2026 | theglobeandmail.comVentyx Biosciences, Inc. Investigated by the Portnoy Law FirmApril 29, 2026 | globenewswire.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 24 at 1:00 AM | Profits Run (Ad)Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYXFebruary 5, 2026 | businesswire.comAssessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B MultipleJanuary 26, 2026 | finance.yahoo.comVentyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYXJanuary 23, 2026 | prnewswire.comHalper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their RightsJanuary 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYXJanuary 15, 2026 | prnewswire.comSee More Headlines VTYX Stock Analysis - Frequently Asked Questions How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) posted its quarterly earnings data on Thursday, November, 6th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.13. When did Ventyx Biosciences IPO? Ventyx Biosciences (VTYX) raised $152 million in an initial public offering on Wednesday, October 20th 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share. What other stocks do shareholders of Ventyx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ventyx Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Micron Technology (MU), MARA (MARA) and Atai Beckley (ATAI). Company Calendar Last Earnings11/06/2025Today10/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (15m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 VTYX's financial health is in the Green zone, according to TradeSmith. VTYX has been in this zone for over 15 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VTYX CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees30Year Founded2018Price Target and Rating Average Price Target for Ventyx Biosciences$14.00 High Price Target$14.00 Low Price Target$14.00 Potential Upside/Downside0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$135.12 million Net MarginsN/A Pretax MarginN/A Return on Equity-48.11% Return on Assets-43.89% Debt Debt-to-Equity RatioN/A Current Ratio17.86 Quick Ratio17.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.59 per share Price / Book3.90Miscellaneous Outstanding Shares71,761,000Free Float61,363,000Market Cap$1.00 billion OptionableOptionable Beta1.26 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:VTYX) was last updated on 3/4/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredHow I’m playing the AI melt-up (and down)Porter Stansberry says a powerful new market shift is forming and most investors are missing it entirely. I...Porter & Company | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
